- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2017
- Public Summary Document (PSD) November 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2017 PBAC Meeting - Word
Obinutuzumab – November 2017
Obinutuzumab: Solution for I.V. infusion 1000 mg in 40 mL; Gazyva®
Last updated
16 March 2018